The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’
George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’View Video
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America
Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin AmericaView Video

Latest Share Chat

Pin to quick picksTILS.L Share News (TILS)

  • There is currently no data for TILS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Tiziana extends ADS sales agreement with ThinkEquity

Fri, 12th Jun 2020 09:39

(Sharecast News) - Tiziana Life Sciences announced an extension to the current 'at the market sales agreement' with ThinkEquity, a division of Fordham Financial Management, on Friday.
The AIM-traded firm entered into the agreement with ThinkEquity as sales agent on 15 April, under which it could offer and sell through ThinkEquity American Depositary Shares (ADS).

It said each ADS represented five ordinary shares, having an aggregate offering price of up to $20m (£15.84m).

"The offering of ADSs pursuant to the offering agreement continues to run and will now terminate upon the earlier of the sale of all of the ADSs subject to the offering agreement, the termination of the offering agreement by ThinkEquity or the company, as permitted in accordance with its terms, or 31 July, unless extended," the Tiziana board said in its statement.

At 0938 BST, shares in Tiziana Life Sciences were up 1.49% at 88.8p.
More News

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.